Larimar Therapeutics (LRMR) EPS (Basic) (2016 - 2020)
Historic EPS (Basic) for Larimar Therapeutics (LRMR) over the last 8 years, with Q1 2020 value amounting to -$0.59.
- Larimar Therapeutics' EPS (Basic) fell 6914.19% to -$0.59 in Q1 2020 from the same period last year, while for Sep 2020 it was -$0.68, marking a year-over-year increase of 9210.71%. This contributed to the annual value of -$7.46 for FY2019, which is 29254.75% down from last year.
- Larimar Therapeutics' EPS (Basic) amounted to -$0.59 in Q1 2020, which was down 6914.19% from -$1.2 recorded in Q4 2019.
- In the past 5 years, Larimar Therapeutics' EPS (Basic) ranged from a high of -$0.35 in Q1 2019 and a low of -$2.11 during Q3 2019
- Its 5-year average for EPS (Basic) is -$0.72, with a median of -$0.54 in 2016.
- As far as peak fluctuations go, Larimar Therapeutics' EPS (Basic) surged by 5584.8% in 2016, and later tumbled by 41577.38% in 2019.
- Quarter analysis of 5 years shows Larimar Therapeutics' EPS (Basic) stood at -$0.38 in 2016, then fell by 24.73% to -$0.48 in 2017, then increased by 18.23% to -$0.39 in 2018, then crashed by 207.63% to -$1.2 in 2019, then skyrocketed by 50.66% to -$0.59 in 2020.
- Its EPS (Basic) stands at -$0.59 for Q1 2020, versus -$1.2 for Q4 2019 and -$2.11 for Q3 2019.